Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study
Chan Yoon Cheah, David Belada, Michelle A Fanale, Andrea Janikova, Myron S Czucman, Ian W Flinn, Amy V Kapp, Avi Ashkenazi, Sean Kelley, Gordon L Bray, Scott Holden, John F Seymour
The Lancet Haematology | ELSEVIER SCI LTD | Published : 2015
This study was funded by Genentech (South San Francisco, CA, USA) and Amgen (Thousand Oaks, CA, USA). We thank the patients, carers, investigators, sub-investigators, and research nurses who participated in the study.